PSMA-PET for Lymph Node Detection in Recurrent Prostate Cancer: How do we use the Magic Bullet?

Affiliations

¹ Department of Urology, Technical University of Munich, Munich, Germany.
² Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia; Australian Prostate Cancer Research Centre, Epworth Healthcare, Richmond, Australia; The Sir Peter MacCallum Department of Oncology, University of Melbourne.
³ Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Australia; The Sir Peter MacCallum Department of Oncology, University of Melbourne.
⁴ Department of Nuclear Medicine, Technical University of Munich, Munich, Germany; Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.

Editorial

Tobias Maurer et al. Theranostics. 2017.

. 2017 May 15;7(7):2046-2047.

doi: 10.7150/thno.20855. eCollection 2017.

¹ Department of Urology, Technical University of Munich, Munich, Germany.
² Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia; Australian Prostate Cancer Research Centre, Epworth Healthcare, Richmond, Australia; The Sir Peter MacCallum Department of Oncology, University of Melbourne.
³ Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Australia; The Sir Peter MacCallum Department of Oncology, University of Melbourne.
⁴ Department of Nuclear Medicine, Technical University of Munich, Munich, Germany; Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.

No abstract available

Comment on

Diagnostic Accuracy of Ga-68-HBED-CC-PSMA-Ligand-PET/CT before Salvage Lymph Node Dissection for Recurrent Prostate Cancer.
Jilg CA, Drendel V, Rischke HC, Beck T, Vach W, Schaal K, Wetterauer U, Schultze-Seemann W, Meyer PT. Jilg CA, et al. Theranostics. 2017 Apr 10;7(6):1770-1780. doi: 10.7150/thno.18421. eCollection 2017. Theranostics. 2017. PMID: 28529650 Free PMC article.

1. Maurer T, Eiber M, Schwaiger M, Gschwend JE. Current use of PSMA-PET in prostate cancer management. Nat Rev Urol. 2016;13:226–35. - PubMed
1. Perera M, Papa N, Christidis D, Wetherell D, Hofman MS, Murphy DG. et al. Sensitivity, Specificity, and Predictors of Positive 68Ga-Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis. European urology. 2016;70:926–37. - PubMed
1. Mottaghy FM, Behrendt FF, Verburg FA. (68)Ga-PSMA-HBED-CC PET/CT: where molecular imaging has an edge over morphological imaging. Eur J Nucl Med Mol Imaging. 2016;43:394–6. - PubMed
1. Budaus L, Leyh-Bannurah SR, Salomon G, Michl U, Heinzer H, Huland H. et al. Initial Experience of (68)Ga-PSMA PET/CT Imaging in High-risk Prostate Cancer Patients Prior to Radical Prostatectomy. European urology. 2016;69:393–6. - PubMed
1. Maurer T, Gschwend JE, Rauscher I, Souvatzoglou M, Haller B, Weirich G. et al. Diagnostic Efficacy of (68)Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer. The Journal of urology. 2016;195:1436–43. - PubMed